Results 61 to 70 of about 9,156,297 (208)

Just Say No…to the Nocebo Effect

Inflammatory Bowel Diseases, 2020
Biosimilars are highly similar products of an innovator biologic used to decrease costs. The nocebo effect is an increase in symptoms resulting from a patient’s negative perceptions about a biosimilar. Multistep notification, organized transition, and opt-out ability constitute a framework for switching patients from a reference product to a biosimilar.
Leah, Rossmann, Raymond K, Cross
openaire   +2 more sources

The impact of contextual factors on nursing outcomes and the role of placebo/nocebo effects: a discussion paper

PAIN Reports, 2019
. Introduction:. Placebo and nocebo effects represent one of the most fascinating topics in the health care field. Objectives:. the aims of this discussion paper were (1) to briefly introduce the placebo and nocebo effects, (2) to elucidate the ...
Alvisa Palese, Giacomo Rossettini, Luana Colloca, Marco Testa   +3 more
doaj   +1 more source

The Nocebo Effect in Childbirth Classes [PDF]

The Journal of Perinatal Education, 2013
Patients are well-known to experience a placebo response to medications or treatments. It is less well-known that they can also experience a nocebo response where they have negative effects from something that should be ineffective. In recent literature, the words of medical providers have been demonstrated to create illness responses without physical ...
openaire   +2 more sources

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Daniel Himelstein, Megan McNicol, Mahmoud Abdel‐Rasoul, Brendan M. Boyle, Hilary K. Michel, Ross Maltz   +5 more
wiley   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Efficacy of open-label counterconditioning for reducing nocebo effects on pressure pain [PDF]

, 2023
Background: Nocebo effects can adversely affect the experience of physical symptoms, such as pain and itch. Nocebo effects on itch and pain have shown to be induced by conditioning with thermal heat stimuli and reduced by counterconditioning.
Meijer, Simone, Karacaoglu, Merve, van Middendorp, Henriët, Simone Meijer, Kaya J. Peerdeman, Merve Karacaoglu, Meijer, S., Karacaoglu, M., Evers, A.W.M., Dieuwke S. Veldhuijzen, Karin B. Jensen, Jensen, Karin B. (author), Peerdeman, K.J., Henriët van Middendorp, Veldhuijzen, Dieuwke S., Meijer, Simone (author), Middendorp, H. van, Karacaoglu, Merve (author), Peerdeman, Kaya J. (author), Evers, A.W.M. (author), van Middendorp, Henriët (author), Jensen, Karin B., Veldhuijzen, D.S., Jensen, K.B., Andrea W. M. Evers, Peerdeman, Kaya J., Veldhuijzen, Dieuwke S. (author)   +26 more
core   +2 more sources

Information About the Optimism of a Placebo/Nocebo Provider and Placebo/Nocebo Side Effects

Frontiers in Psychology, 2021
BackgroundResearch has demonstrated that personality characteristics, such as optimism are associated with placebo/nocebo responding. The present study investigated whether written information about the optimism of a placebo/nocebo provider can influence
Carina Schlintl, Anne Schienle
doaj   +1 more source

Time‐Resolved Multi‐Omics Identify Biomarkers of Immediate Reactions to mRNA Vaccination

Allergy, EarlyView.
We compared early vaccine‐induced immune and metabolic signatures and downstream immunity after second and booster BNT162b2 doses in participants with sARs, ISSRs, or no reactions. Neutrophil mobilization, antiviral programs, and robust anti‐S‐antibody responses occurred across reaction groups.
Ana Olivera, Benjamin Schwarz, Brittany Dulek, Ian S. LaCroix, Min Li, Lindsay Chatman, Muhammad B. Khalid, Ellen Zektser, Karen Laky, Stella Hartono, Eric Bohrnsen, Cole D. Kimzey, Eric Chu, Roa Harb, Pamela A. Frischmeyer‐Guerrerio   +14 more
wiley   +1 more source

Placebo or Nocebo Interventions as Affected by Hypnotic Susceptibility

Applied Sciences, 2023
The purpose of the present study was to examine placebo and nocebo effects under hypnotic analgesia in lowly hypnotizable (LH) and highly hypnotizable (HH) subjects.
Yair Sharav, Yaron Haviv, Michael Tal
doaj   +1 more source

Placebo and nocebo effects

Pain
Abstract We introduce the Psychoneurobiology, Individualization, and Normalization (PIN) framework of placebo and nocebo effects. Traditionally, research primarily focused on psychoneurobiological mechanisms of these effects, the Psychoneurobiology phase.
Belina Rodrigues, Nandini Raghuraman, Roni Shafir, Yang Wang, Lakota Watson, James Cottam, Mumtahana Nabi, Titilola Akintola, Luana Colloca   +8 more
openaire   +2 more sources